Chronic Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Decreases Hypertension, Insulin Resistance, and Hypertriglyceridemia in Metabolic Syndrome
Figure 2
The change in mean arterial pressure (MAP) from baseline in obese (a) and lean (b) SHR-cp during three weeks of vehicle or compound 11 (10 mg/kg/d) administration. compared to vehicle.